688553 Stock Overview
Research and develops, produces, and sells anti-tumor and injection drugs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Sichuan Huiyu Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.56 |
| 52 Week High | CN¥18.64 |
| 52 Week Low | CN¥9.45 |
| Beta | 0.35 |
| 1 Month Change | -6.15% |
| 3 Month Change | 35.42% |
| 1 Year Change | 4.71% |
| 3 Year Change | -53.32% |
| 5 Year Change | n/a |
| Change since IPO | -60.72% |
Recent News & Updates
Sichuan Huiyu Pharmaceutical's (SHSE:688553) Promising Earnings May Rest On Soft Foundations
Nov 02
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Stock Catapults 38% Though Its Price And Business Still Lag The Market
Oct 29Recent updates
Sichuan Huiyu Pharmaceutical's (SHSE:688553) Promising Earnings May Rest On Soft Foundations
Nov 02Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Stock Catapults 38% Though Its Price And Business Still Lag The Market
Oct 29Here's Why Sichuan Huiyu Pharmaceutical (SHSE:688553) Can Manage Its Debt Responsibly
Sep 29Sichuan Huiyu Pharmaceutical (SHSE:688553) Has A Pretty Healthy Balance Sheet
Jun 07Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) 33% Share Price Surge Not Quite Adding Up
Mar 07Shareholder Returns
| 688553 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.1% | -1.7% | -1.0% |
| 1Y | 4.7% | -4.3% | 10.8% |
Return vs Industry: 688553 exceeded the CN Pharmaceuticals industry which returned -4.3% over the past year.
Return vs Market: 688553 underperformed the CN Market which returned 10.8% over the past year.
Price Volatility
| 688553 volatility | |
|---|---|
| 688553 Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688553 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688553's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,364 | Zhao Ding | www.huiyupharma.com |
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor and injection drugs in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, sodium valproate concentrated solution, epirubicin hydrochloride, fulvestrant, milrinone, fluorouracil, sodium thiosulfate, zoledronic acid, zoledronic acid concentrated solution, cisatracurium besylate, bortezomib, octreotide acetate, doxorubicin, and palonosetron hydrochloride. Sichuan Huiyu Pharmaceutical Co., Ltd.
Sichuan Huiyu Pharmaceutical Co., Ltd. Fundamentals Summary
| 688553 fundamental statistics | |
|---|---|
| Market cap | CN¥6.59b |
| Earnings (TTM) | CN¥278.20m |
| Revenue (TTM) | CN¥1.12b |
23.7x
P/E Ratio5.9x
P/S RatioIs 688553 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688553 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.12b |
| Cost of Revenue | CN¥181.22m |
| Gross Profit | CN¥938.56m |
| Other Expenses | CN¥660.37m |
| Earnings | CN¥278.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 83.82% |
| Net Profit Margin | 24.84% |
| Debt/Equity Ratio | 17.4% |
How did 688553 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield32%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 19:49 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sichuan Huiyu Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|